FDA Approves GSK's Jideytro for ROS1-Positive Lung Cancer, First in Class
GSK sits 40% above its 52-week low of $36.34.
Summary
GSK's Jideytro (zidesamtinib) won FDA approval for previously treated ROS1-positive NSCLC, marking the company's first lung cancer drug. The approval came ahead of the September 18 target date, based on a 44% ORR and durable responses in the ARROS-1 trial. This is the first product from the $10.6B Nuvalent acquisition to reach market, validating the deal's oncology strategy. With neladalkib under FDA review for ALK-altered NSCLC and additional pipeline assets, GSK is building a targeted lung cancer franchise. The early approval and strong efficacy data strengthen the investment thesis around the Nuvalent acquisition and GSK's oncology pivot.
At the time of this announcement, GSK was trading at $50.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $101.4B. The 52-week trading range was $36.34 to $61.70. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.